Dr. Yair Lotan, UTSW, presented on BLC with Cysview for surveillance Dr. Yair Lotan M.D., Professor of Urology, UT Southwestern Medical Center and the lead author on a new Consensus paper for use of ...

The FDA has approved Cysview (hexaminolevulinate HCl, from GE Healthcare), an optical imaging agent, for use in the cystoscopic detection of non-muscle-invasive papillary cancer of the bladder among ...

CLEVELAND, Ohio -- In 2010, according to the National Cancer Institute, an estimated 70,000 people in the United States were diagnosed with bladder cancer. An estimated 15,000 people died from the ...

Photocure ASA, the bladder cancer company, announces the start of its Cysview sales, marketing and distribution operations in the Canadian market. In August 2021 Photocure had reached an agreement ...

OSLO, Norway, June 23, 2021 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology. The study objective was to determine the ...

FOX CHASE, Pa. -- Bladder cancer is one of the most common cancers - just behind melanoma. Yet, many people don't know much about it. Doctors are now using a diagnostic tool to better find and ...

(RTTNews) - Photocure ASA (PHCUF.PK), a Norwegian specialty pharma company, said on Monday that it has started sales, marketing, and distribution operations of Cysview in Canada. Cysview is an optical ...

OSLO, Norway, Nov. 5, 2019 /PRNewswire/ -- Photocure ASA., (OSE: PHO), The United States Centers for Medicare and Medicaid Services (CMS) has released its Final Rule maintaining the reimbursement code ...

(StatePoint) When Cameron Todd was diagnosed with prostate cancer in 2017, he never imagined that just two and a half months later, his doctors would diagnose him with bladder cancer. Concerned about ...